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Background: Interactions between cancer cells and surrounding cancer-associated fibroblasts (CAFs) play an
important role in cancer progression. Invasive ductal carcinoma (IDC) of the pancreas is characterized by abundant
fibrous connective tissue called desmoplasia. Podoplanin (PDPN) is a lymphatic vessel marker (D2-40), and
expression of PDPN by stromal CAFs has been reported to be a prognostic indicator in various types of cancer.
Methods: Expression of PDPN in pancreatic IDCs was assessed by immunohistochemical examination in 105
patients who underwent pancreatic resection. Primary CAFs were established from pancreatic cancer tissue
obtained by surgery. Quantitative reverse transcription-polymerase chain reaction and flow cytometric analysis were
performed to investigate PDPN expression in CAFs. We sorted CAFs according to PDPN expression, and analyzed
the functional differences between PDPN+ CAFs and PDPN– CAFs using indirect co-culture with pancreatic cancer
cell lines. We also investigated the culture conditions to regulate PDPN expression in CAFs.
Results: PDPN expression in stromal fibroblasts was associated with lymphatic vessel invasion (P = 0.0461), vascular
invasion (P = 0.0101), tumor size ≥3 cm (P = 0.0038), histological grade (P = 0.0344), Union for International Cancer
Control classification T stage (P = 0.029), and shorter survival time (P < 0.0001). Primary CAFs showed heterogeneous
PDPN expression in vitro. Moreover, migration and invasion of pancreatic cancer cell lines (PANC-1 and SUIT-2) were
associated with PDPN expression in CAFs (P < 0.01) and expression of CD10, matrix metalloproteinase (MMP) 2, and
MMP3. In cultured CAFs, PDPN positivity changed over time under several conditions including co-culture with
cancer cells, different culture media, and addition of growth factor.
Conclusions: PDPN-expressing CAFs enhance the progression of pancreatic IDC, and a high ratio of PDPN-
expressing CAFs is an independent predictor of poor outcome. Understanding the regulation of the tumor
microenvironment is an important step towards developing new therapeutic strategies.
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Pancreatic cancer is one of the most lethal types of cancer.
Improvements in the survival of pancreatic cancer patients
have been minimal, and the 5-year survival rate remains
low [1]. The poor prognosis is related to the difficulty of
early diagnosis because of the absence of symptoms, and
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reproduction in any medium, provided the orsuch as chemotherapy and radiotherapy [2]. Invasive pan-
creatic cancer tissue includes cancer, inflammatory, and fi-
broblastic cells, which interact with each other to create
the local microenvironment. Fibroblasts recruited by the
cancer tissue are called cancer-associated fibroblasts
(CAFs), and play an important role in cancer progression
[3,4]. The poor prognosis of pancreatic adenocarcinoma is
partially due to the fibroblastic reaction called desmopla-
sia, which induces a hypovascular environment [5], ineffi-
ciency of drug delivery, and tumor-stromal interactions
such as secretion of growth factors [6].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.molecular-cancer.com/content/12/1/168In 1998, pancreatic stellate cells (PSCs) were identified in
the pancreas [7,8]. In the normal pancreas, PSCs are located
close to the acinar cells, and retain abundant vitamin A-
containing lipid droplets in their cytoplasm as a quiescent
phenotype [9]. PSCs can obtain a myofibroblast-like morph-
ology and immunoreactivity for alpha-smooth muscle actin
(α-SMA) by inflammatory stimulation or signals from can-
cer cells, such as interleukin (IL)-1, IL-6, tumor necrosis
factor-alpha, platelet-derived growth factor, transforming
growth factor (TGF)-β1, and activin A [10]. Activated PSCs
produce abundant extracellular matrix (ECM), leading to
cancer progression [9,11]. In addition, activated PSCs har-
vested by the outgrowth method have characteristics similar
to those of CAFs. Recently, CAFs have gained attention as a
potential therapeutic target [12,13].
Podoplanin (PDPN) is a 38–44 kDa O-glycosylated
transmembrane glycoprotein that is selectively expressed
by lymphatic endothelial cells [14]. PDPN is also expressed
by normal kidney podocytes [15], alveolar type I cells [16],
basal epidermal keratinocytes [17], and mesothelial cells
[18,19]. Several types of cancer may also express PDPN,
such as squamous cell carcinomas [20,21], soft tissue tu-
mors [22], and brain tumors [23]. PDPN-expressing can-
cer cells have enhanced malignant potential due to
enhancement of platelet aggregation, which promotes me-
tastasis [24,25], alteration of cell morphology and motility
[26,27], and epithelial-mesenchymal transition [28]. Stro-
mal fibroblasts surrounding cancer cells may also express
PDPN [29-36]. The presence of PDPN-expressing fibro-
blasts has been reported to be a prognostic indicator in
several types of cancer, but outcomes vary according to
the type of cancer [30,33-36]. Understanding the molecu-
lar mechanisms of PDPN expression is important for the
development of new therapeutic strategies for the treat-
ment of malignant tumors with PDPN-positive fibroblasts.
In this study, we examined PDPN expression in inva-
sive ductal carcinoma (IDC) of the human pancreas
using immunohistochemical methods, and investigated
the functional roles of PDPN-expressing CAFs estab-
lished from pancreatic IDCs by cell sorting. CD10+ PSCs
were previously found to enhance the progression of
pancreatic cancer in a similar manner to CAFs, depend-
ing on matrix metalloproteinase (MMP) 3 secretion [13].
In this study, we found that PDPN+ and PDPN– CAFs
had functional differences associated with their expres-
sion of CD10, MMP3, and MMP2. We also found that
PDPN expression in CAFs was affected by both cancer
cell-stromal interactions and environmental conditions.
Results
Correlations between PDPN expression in fibroblasts and
clinicopathologic characteristics
Numerous fibroblasts were observed in the area of can-
cerous invasion (Figure 1A-a), and PDPN+ fibroblastswere observed close to the tumor cells (Figure 1A-b). In
normal pancreatic tissue including the main pan-
creatic duct, PDPN+ fibroblasts were rarely observed
(Figure 1A-c). PDPN+ fibroblasts (≥30%) were ob-
served in 70.5% (74/105) of pancreatic IDCs, but no
PDPN+ cancer cells were observed. Patients in the PDPN+
group had more frequent lymphatic invasion (P = 0.0461),
vascular invasion (P = 0.0101), tumor size ≥3 cm (P =
0.0038), G3 grade tumor (P = 0.0344), and Union for Inter-
national Cancer Control (UICC) grade pT3 or higher (P =
0.029) than patients in the PDPN– group (Table 1). These
results suggest that PDPN+ stromal fibroblasts are associ-
ated with tumor progression and the invasiveness of cancer
cells.
Stromal PDPN expression is independently associated
with shorter survival time
PDPN+ stromal fibroblasts were associated with shorter
patient survival and disease-free survival times (Figure 1B,
C). The median survival times for PDPN+ and PDPN–
cases were 14 and 33 months, respectively. Multivariate
survival analysis based on the Cox proportional hazards
model including all parameters found to be significant on
univariate analyses (data not shown), including PDPN
positivity, lymphatic invasion, vascular invasion, tumor
size ≥3 cm, G3 tumor, UICC grade pT3/4, UICC grade
pN1, and stage III/IV (Table 2) [37], found that PDPN
positivity (relative risk 2.598, P = 0.0030) and UICC N1
category (P = 0.0302) were independent markers of poor
prognosis (Table 2) [37].
CAFs have heterogeneous PDPN expression
We investigated PDPN mRNA expression in 22 CAF
cultures that were numbered from 1 to 22 by quantita-
tive reverse transcription-polymerase chain reaction
(qRT-PCR) (Figure 2A). Primary CAF cultures expressed
various levels of PDPN mRNA, and CAF1 cells showed
significantly high expression. The pancreatic cancer cell
line PANC-1 did not express PDPN mRNA. Flow cyto-
metric analysis showed that cultured CAFs exhibited
various positivity rates (0.4–94%) for PDPN in accord-
ance with the results of qRT-PCR (Figure 2B). We con-
firmed that PDPN expression had not been affected by
proteolysis during trypsin/EDTA treatment using flow
cytometric analysis (Additional file 1: Figure S1A), and
immunocytochemical staining of CAFs (Additional file 1:
Figure S1B). All the primary cultured CAFs (CAF1, CAF2,
CAF3, and CAF4) were positive for fibroblast activation
protein-alpha (FAP) in most cells (Additional file 1: Figure
S1C). Immunofluorescence staining showed CAFs as
spindle-shaped and stellate-like cells, and almost all cells
were stained for α-SMA and partly stained for PDPN




































Figure 1 Immunohistochemical staining for PDPN in IDC of the pancreas. (A-a) Pancreatic IDCs consisted of cancer cells and stromal cells
such as CAFs. (A-b) CAFs around the cancer cells were positive for PDPN. (A-c) In the normal main pancreatic duct, stromal cells were rarely
positive for PDPN. The arrow indicates lymphatic vessels as a positive control. (B, C) Stromal PDPN expression was associated with a worse overall
survival rate (B) and disease-free survival rate (C) by Kaplan-Meier survival analysis.
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To investigate the effects of CAFs on the invasiveness of
pancreatic cancer cells, we used a transwell co-culture sys-
tem as described previously [13]. Fujita et al. [38] reported
that the proliferation of pancreatic cancer cells was not
enhanced by the conditions of an indirect co-culture sys-
tem. We confirmed those findings, and assumed that the
increase in invasiveness of cancer cells was not accelerated
by the proliferation of cancer cells. PANC-1, SUIT-2, andKP2 pancreatic cancer cells were co-cultured with CAF1
(high PDPN-expressing cells) or CAF2 (PDPN– cells) in
the transwell system. Pancreatic cancer cells strongly mi-
grated (Figure 3A,B) and invaded (Figure 3C,D) when co-
cultured with CAF1 cells. On the other hand, CAF2 cells
had a lesser effect on migration and invasion of co-
cultured cancer cells. Therefore, we hypothesized that the
differences in the invasive potential of cancer cells were
due to PDPN expression in CAFs.
Table 1 Relationships between PDPN expression and clinicopathologic factors
Characteristics PDPN negative, n = 31 (29.5%) PDPN positive, n = 74 (70.5%) p Value
Lymphatic invasion No 11(35.5) 13(17.6) 0.0461*
Yes 20(64.5) 61(82.4)
Vascular invasion No 17(54.8) 21(28.4) 0.0101*
Yes 14(45.2) 53(71.6)
Tumor size <3 cm 23(74.2) 32(43.2) 0.0038*
≥3 cm 8(25.8) 42(56.8)
Histologic Grade G1/G2 20(64.5) 31(41.9) 0.0344*
G3 11(35.5) 43(58.1)
UICC pT1/pT2 8(25.8) 7(9.5) 0.0290*
T category pT3/pT4 23(74.2) 67(90.5)
UICC pN0 14(45.2) 20(27.0) 0.0701
N category pN1 17(54.8) 54(73.0)
UICC stage I 7(22.6) 5(6.8) 0.0642
II 23(74.2) 65(87.8)
III/IV 1(3.2) 4(5.4)
Significant differences between samples are indicated as *P < 0.05. UICC, Union for International Cancer Control.
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cancer cells more effectively than PDPN– CAFs
To clarify the differences in enhancement of invasive po-
tential between PDPN+ and PDPN– CAFs, we sorted
CAFs by magnetic-activated cell sorting (Additional file 2:
Figure S2A). The level of PDPN mRNA expression in
PDPN+ and PDPN– CAFs derived from CAF3 and
CAF4 cells was consistent with the level of PDPN
expression found by flow cytometry (Additional file 2:
Figure S2B). We investigated the effects of these two
populations on the invasiveness of PANC-1 and SUIT-2
cells using migration and invasion assays in a co-culture
system. PDPN+ CAF3 and CAF4 cells enhanced the mi-
gration (Figure 4A) and invasion (Figure 4B) of PANC-1
and SUIT-2 cells more strongly than PDPN– CAFs







UICC T category 0.245
UICC N category 2.07
UICC Stage
NOTE. The relative risk of the UICC stage is not shown because it is comprised of tw
International Cancer Control, 7th edition.Knockdown of PDPN in CAFs has no effect on the
enhancement of invasiveness of pancreatic cancer cells
PDPN is a known transmembrane protein, but not a se-
creted protein. Despite no detection of PDPN in culture
supernatants of CAFs (data not shown), PDPN+CAFs had
a promoting effect on cancer cell invasion in the indirect
co-culture system. We compared CAF1 cells with and
without PDPN knockdown by small interfering RNA
(siRNA) (Additional file 3: Figure S3A,B) to clarify the
functional role of PDPN. There were no changes in migra-
tion (Additional file 3: Figure S3C) or invasion (Additional
file 3: Figure S3D) of PANC-1 and SUIT-2 cells when they
were co-cultured with PDPN-knockdown CAF1 cells.
These data suggest that PDPN itself has no effect on the
invasion and migration of pancreatic cancer cells, whereas
PDPN+CAFs promote these features.of conventional prognostic factors and PDPN expression


























































































































α-SMA PDPN DAPI Merge
Figure 2 PDPN expression was heterogeneous in CAFs. (A) qRT-PCR showed variable PDPN expression in CAFs. The pancreatic cancer cell line
PANC-1 expressed less PDPN mRNA than CAFs. (B) Flow cytometry showed 0.4–94% positivity rates for PDPN expression. Representative flow
cytometry data for PDPN expression in CAF1 cells are shown (right). (C) Immunofluorescence staining for PDPN (green) and α-SMA (red) in CAF4.
CAFs had spindle-shaped or stellate-like morphology and expressed α-SMA and PDPN. Original magnification × 100.
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expression between PDPN+ and PDPN– CAFs
To detect differences between PDPN+ and PDPN– CAFs,
we analyzed the mRNA and protein from various CAFs
(CAF1, CAF2, and CAF3 and CAF4 cells sorted by PDPN
expression). CAF1 cells and PDPN+CAFs expressed more
CD10, MMP3, and MMP2 than CAF2 cells and PDPN–
CAFs (Figure 5A). CD10 is a cell surface metalloproteinase,
and MMPs promote cancer cell invasion by degrading
structural ECM proteins [39,40]. In particular, CD10+
PSCs have been reported to promote cancer-stromalinteractions by secreting high levels of MMP3 [13]. The
level of PDPN protein expression in CAFs was correlated
with that of CD10 expression (Figure 5B), which was also
the trend observed in qRT-PCR analysis. These findings
suggest that PDPN+CAFs in pancreatic cancer play a piv-
otal role in increasing the invasive potential of cancer cells.
The number of PDPN+ CAFs is increased through
cancer-stromal interactions
We investigated the effects of cancer cells on PDPN expres-

























































































PANC-1 SUIT-2 KP-2 PANC-1 SUIT-2 KP-2
Figure 3 Effects of CAFs (CAF1 and CAF2 cells) on the invasive potential of pancreatic cancer cells. CAF1 (high PDPN-expressing cells)
promoted the migration (A, B) and invasion (C, D) of PANC-1, SUIT-2, and KP-2 cells compared with CAF2 (PDPN– cells). Significant differences
between sample means are indicated as *P < 0.05, **P < 0.01. (B, D) Representative photomicrographs of migrating (B) and invading (D) cancer
cells co-cultured with CAFs (hematoxylin and eosin staining; original magnification × 40).
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http://www.molecular-cancer.com/content/12/1/168co-cultured with a variety of pancreatic cancer cell lines in
Dulbecco’s modified Eagle’s medium (DMEM) / 2% fetal
bovine serum (FBS), the populations of PDPN-expressing
CAFs increased in a time-dependent manner, especially
CAF4 on day 5, compared with CAF monocultures
(Figure 6). The numbers of CAF4 were almost same on
days 3 and 5, indicating a possible change in the expression
pattern from PDPN– to PDPN+ .
The number of PDPN+ CAFs is affected by the culture
conditions
In co-cultures, all cancer cell lines significantly increased
PDPN expression in CAF4 cells on day 5. Therefore, wehypothesized that PDPN expression was not only affected
by specific signals, but also by environmental conditions.
Wicki et al. [27] reported that PDPN expression in the
breast cancer cell line MCF7 is up-regulated by stimulat-
ing growth factors such as TGF-β, fibroblast growth factor
(FGF)-2, and epidermal growth factor (EGF). However,
when we added the growth factors TGF-β1, FGF-2,
insulin-like growth factor (IGF)-1, and EGF to serum-free
DMEM, PDPN+ populations among CAF3 and CAF4 cells
mostly decreased in a time-dependent manner (Figure 7A).
In CAF4 cell cultures, however, addition of FGF-2 or IGF-
1 had a lesser effect on PDPN+ populations (Figure 7A).
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Figure 4 Effects of sorted CAFs on the invasiveness of pancreatic cancer cells. PDPN+ CAFs promoted the migration (A) and invasion
(B) of PANC-1 and SUIT-2 cells compared with PDPN– CAFs. The P values for the migration assays were: P = 0.0001 (PANC-1 with CAF3),
P = 0.0003 (PANC-1 with CAF4), P = 0.0034 (SUIT-2 with CAF3), and P = 0.0058 (SUIT-2 with CAF4). The P values for the invasion assays were:
P = 0.0013 (PANC-1 with CAF3), P = 0.0022 (PANC-1 with CAF4), P = 0.0065 (SUIT-2 with CAF3), and P = 0.0013 (SUIT-2 with CAF4). Significant
differences between sample means are indicated as **P < 0.01.
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http://www.molecular-cancer.com/content/12/1/168populations. We compared PDPN+ populations among
CAF3 and CAF4 cells when cultured in DMEM with or
without several concentrations of FBS. Control cells were
cultured in DMEM with 10% FBS, and the medium was
changed every day. Addition of FBS attenuated the
increasing rate of PDPN+ populations, depending on
the FBS concentration. However, PDPN+ cells among
CAFs increased in a time-dependent manner despite ad-ministration of FBS (Figure 7B). In addition, the popula-
tions of PDPN+CAFs cultured in serum-free DMEM in-
creased more significantly than those cultured in glucose-
and serum-free DMEM (Figure 7C). These findings suggest
that PDPN+CAFs are affected by culture conditions, and
PDPN+ populations increase in a time-dependent manner
when cultured in DMEM containing glucose and decrease
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Figure 5 Differences between PDPN+ and PDPN– CAFs. (A) qRT-PCR analyses showed that the levels of PDPN mRNA expression in CAFs were
significantly correlated with the levels of CD10, MMP2, and MMP3 mRNA expression. Significant differences between sample means are indicated
as **P < 0.01. (B) Western blot analysis showed that PDPN protein expression in CAFs was also associated with CD10 protein expression.
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In the present study, PDPN-expressing CAFs were found
in IDC tissue of the pancreas. We revealed the signifi-
cance of these cells in terms of cancer cell invasion, in
correlation with shorter patient survival and several bio-
logical factors, namely lymphatic and vascular invasion,
larger tumor size, histological grade, and UICC T grade
[37]. Kitano et al. [33] assessed PDPN-expressing stro-
mal spindle cells in multiple cancer tissues includingpancreatic cancer using tissue microarrays. They found a
73% (16/22) positivity rate for PDPN expression in pan-
creatic cancer. In this study, positive PDPN expression
was found in 70.5% (74/105) of cases when we defined
the cutoff value in stromal fibroblasts as 30%. We there-
fore consider this to be an appropriate cutoff value.
In recent clinicopathological studies of other cancer
types, PDPN expression in the cancerous stroma was re-














Figure 6 Percentage of PDPN+ cells among CAFs indirectly co-cultured with pancreatic cancer cells. CAFs were co-cultured with the
indicated pancreatic cancer cell lines for several days, and then the percentage of PDPN+ CAFs was assessed by flow cytometry.
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http://www.molecular-cancer.com/content/12/1/168prognosis varied depending on the cancer type. High
PDPN expression in fibroblasts is significantly correlated
with a poor prognosis in IDC of the breast [34], lung
adenocarcinoma [31-33], and ovarian carcinoma [36].
Conversely, PDPN-expressing fibroblasts indicate a fa-
vorable outcome in colorectal carcinoma [35] and uter-
ine cervical carcinoma [30].
Some of the biological functions of PDPN in cancer
cells have been partially elucidated in several studies, but
the biological characteristics of PDPN-expressing stro-
mal fibroblasts are largely unknown. Yamanashi et al.
[35] showed increased invasion of colorectal cancer cellswhen they were co-cultured with fibroblasts with PDPN
knockdown by siRNA. However, the interactions be-
tween the cells were not described, and the fibroblasts
were from a colonic fibroblast cell line (CCD112CoN
from 22 weeks of gestation) rather than from cancer
tissue.
Knockdown of PDPN by siRNA had no effect on the
enhancement of cancer cell invasiveness in our study.
However, Hoshino et al. [31] reported that PDPN-
expressing CAFs in lung adenocarcinoma promote
tumor formation both in vivo and in vitro using trans-
fection by short hairpin RNA against PDPN expression.
Figure 7 Populations of PDPN+ cells among CAFs affected by environmental conditions. (A) The percentage of PDPN+ cells among CAFs
changed in a time-dependent manner by culturing with DMEM-containing growth factors. (B) Populations of PDPN+ cells among CAFs changed
by the addition of FBS in concentration- and time-dependent manners. The control (CTRL) condition consisted of DMEM containing 10% FBS and
medium changes every day. (C) Populations of PDPN+ cells in cultures of serum-free DMEM increased more rapidly than those in cultures of
glucose- and serum-free DMEM.
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http://www.molecular-cancer.com/content/12/1/168According to transfection studies in human MCF7
breast cancer cells, PDPN expression results in morpho-
logical changes, induction of migratory phenotypes with
a significant decrease in cellular stress fibers, and an in-
crease in filopodia-like protrusions [27]. In our study,
PDPN knockdown CAFs did not show any notable
changes in morphology compared with parental CAFs(data not shown). The differences in alteration of
morphology might therefore be dependent on the cell
type.
PSCs were originally identified as the source of fibrosis
in chronic pancreatitis [7], and were assumed to be the
source of desmoplasia in pancreatic cancers. We used
PSCs obtained by the outgrowth method as CAFs,
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and are positive for α-SMA and vimentin, which is simi-
lar to CAFs. It was therefore very difficult to differentiate
between PSCs and CAFs on immunohistochemical stain-
ing. The characteristic differences in CAFs originating
from different tumors might be explained by them ori-
ginating from diverse sources, such as resident local fi-
broblasts, bone marrow-derived progenitor cells, and
transdifferentiation of epithelial/endothelial cells by epi-
genetic transition [41]. Vascular adventitial fibroblasts in
lung adenocarcinoma have biological functions similar
to those of CAFs, and PDPN is highly expressed in vas-
cular adventitial fibroblasts in association with cancer
progression [31]. The differences in biological function
of PDPN+ CAFs in diverse cancers might therefore be
based on the characteristics of their origins.
With the increasing understanding of the roles of CAFs,
various discussions exist regarding their origins, specific
markers, and characteristics [42]. Erez et al. [43] reported
the differences in proinflammatory genes as signature
genes between normal fibroblasts and CAFs in pancreatic
ductal adenocarcinoma especially in mice. Cyclooxygenase
2, Chemokine (C-X-C motif) ligand (CXCL) 1, CXCL2,
cysteine-rich 61, IL-1β, IL-6, and osteopontin differed in
their mRNA expression. When we investigated these sig-
nature genes in our CAFs (CAF1, CAF2, CAF3+/−, and
CAF4+/−), the results were variable, and were not associ-
ated with PDPN expression (data not shown). Several
markers for CAFs have been identified, including α-SMA
and FAP. In previous studies, FAP-expressing fibroblasts
were reported to enhance the cancer cell invasion by pro-
ducing ECM [44], and have essential functions in main-
taining muscle mass and hematopoiesis [45]. Most of the
primary cultured CAFs in our study were α-SMA positive
[13] and FAP positive.
The interactions among cancer cells, stromal cells
such as CAFs, and inflammatory cells create the tumor
microenvironment, and remodel the surrounding ECM
when cancer cells become invasive. Growth factors also
have important effects on adjacent cells in an autocrine
and paracrine fashion [11]. In addition, MMPs are
known to play important roles in cell migration and deg-
radation of the surrounding ECM [40].
In our laboratory, Fujita et al. reported that condi-
tioned medium from PSCs established by the outgrowth
method enhanced colony formation of SUIT-2 cells in
the same way as co-culture. However, colony formation
of MIAPaCa-2 cells was not enhanced by the condi-
tioned medium [46]. Ikenaga et al. revealed that CD10-
expressing PSCs promoted the invasiveness of cancer
cells by secreting MMP3, which was confirmed in the
supernatant [13]. Hwang et al. also reported that condi-
tioned medium from PSCs stimulated cancer cell prolif-
eration, invasion, and colony formation [3]. The effect ofPDPN expression on the conditioned medium of CAFs
in this study was unclear. However it is likely that this
medium would have similar effects on the invasiveness
of cancer cells as co-culture with CAFs, given the differ-
ences in CD10 expression and MMP secretion between
PDPN-positive and -negative CAFs.
FBS contains high concentrations of embryonic
growth-promoting factors, and is widely used as a
growth supplement to enhance cell survival and prolifer-
ation, although the composition of FBS is not fully
understood. We found that PDPN+ CAFs were import-
ant modulators of MMP expression. In addition, the re-
duction in the numbers of PDPN+ CAFs after addition
of growth factors or high concentrations of FBS suggests
the possibility of negative feedback by growth factors.
Conclusions
Although the molecular mechanisms of PDPN expres-
sion in CAFs are not clear, and CAFs have functional
heterogeneity, we found that PDPN+ CAFs play an im-
portant role in cancer cell invasion in association with
the expression of CD10, MMP2, and MMP3. It is im-
portant to develop new therapeutic strategies to target
the supportive microenvironment provided by cancer-
stromal interactions in pancreatic cancer.
Methods
Patients and pancreatic tissue
Pancreatic cancer tissue was obtained from 105 patients
who underwent pancreatic resection for IDC of the pan-
creas at our institution from 1995 to 2011. The clinico-
pathologic characteristics of the patients are shown in
Additional file 4: Table S1. The patients included 70 men
and 35 women with a median age of 65 years (range: 43–
86 years). Survival was measured from the time of pancre-
atic resection until death or censor. The follow-up dur-
ation ranged from 1 to 137 months, and the median
overall survival time was 19 months. Seventy-three pa-
tients died during follow-up. The histological diagnosis of
the specimens was confirmed according to the criteria of
the updated World Health Organization classification
[47]. The tumor stage was assessed according to the UICC
classification, 7th edition [37]. Lymphatic and vascular in-
vasion were detected by hematoxylin and eosin staining.
When necessary, we performed D2-40 (PDPN) staining to
determine lymphatic invasion and Elastica van Gieson
staining to determine vascular invasion. Patients were di-
vided into groups for statistical analysis as shown in
Table 1. We also obtained 20 normal pancreatic tissue
samples from intact pancreatic specimens that were
resected for solid-pseudopapillary neoplasm or neuroen-
docrine tumor, as control tissue. This study was approved
by the Ethics Committee of Kyushu University (approval
number 25–23, 24–222) and was conducted according to
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enacted by the Japanese Government and the Helsinki
Declaration.
Cells and culture conditions
Human CAFs were isolated from fresh surgical specimens
of pancreatic cancer using the outgrowth method [8]. Pri-
mary cultures of CAFs derived from 22 patients with inva-
sive pancreatic cancer were established in our laboratory.
The cell type was confirmed by a spindle-shaped morph-
ology and immunofluorescence staining for α-SMA and
vimentin [13,48]. Passage 3–8 cells were used for assays.
In addition, the following 10 pancreatic cancer cell lines
were used: PANC-1, SUIT-2, KP-2, and AsPC-1 (Dr.
Iguchi, National Shikoku Cancer Center, Matsuyama,
Japan); MIAPaCa-2 (Japanese Cancer Resource Bank,
Tokyo, Japan); BxPC-3, Capan-2, CFPAC-1, and SW 1990
(American Type Culture Collection, Manassas, VA); and
HPC-3 (Dr. Yasoshima, Sapporo Medical University,
Hokkaido, Japan). The lung squamous cancer cell line
H157 (Dr. Onimaru, Kyushu University, Fukuoka, Japan)
was used as a positive control for PDPN expression
[20]. Cells were maintained as described previously [20,49].
In the PDPN induction assay, DMEM (Sigma Chemical
Co., St. Louis, MO) or DMEM containing no glucose
(Invitrogen, Carlsbad, CA) was used for cell culture. Media
were supplemented with 2% or 10% fetal bovine serum
(FBS) (Invitrogen), 10 ng/ml TGF-β1 (R&D, Oxon, UK),
50 ng/ml FGF-2 (Sigma, Basel, Switzerland), 100 ng/ml
IGF-1 (R&D), and 100 ng/ml EGF (Sigma).
Immunohistochemical procedures and evaluation
Immunohistochemical staining was conducted as described
previously [29]. Formalin-fixed, paraffin-embedded tissue
was cut at 4-μm thicknesses and deparaffinized with xylene
and ethanol. The endogenous peroxidase activity was
blocked by methanol containing 0.3% hydrogen peroxidase.
Antigen retrieval was performed by boiling in a microwave
oven (citrate buffer, pH 6.0). The sections were incubated
overnight at 4°C with primary antibodies against PDPN
(413541; mouse monoclonal, D2-40; Nichirei Bioscience,
Tokyo, Japan) and α-SMA (A2547; mouse monoclonal,
1:400; Sigma, St Louis, MO). The immune complexs were
then visualized using EnVision Detection System (Dako,
Glostrup, Denmark) and 3,3′-diaminobenzidine (DAB) Kit
(Dako). We performed immunohistochemical staining for
PDPN and α-SMA in consecutive sections, and fibroblast-
like cells involved with the cancer cells or cancer ducts
were α-SMA positive, as shown in a previous report [46].
We confirmed the cell type by a spindle-shaped morph-
ology and α-SMA positivity. PDPN was also expressed by
such fibroblast-like cells, and we assumed those cells to be
CAFs. All sections were evaluated independently by two
investigators without any knowledge of the clinicalfeatures. Stromal expression of PDPN was defined as posi-
tive when over than 30% of the stromal fibroblasts around
neoplastic cells were stained. The stromal cells around nor-
mal pancreatic ducts were also evaluated in 20 cases of
normal pancreatic tissue. PDPN expression was not ob-
served in any carcinoma cells. Lymphatic vessels stained
positive for PDPN without exception, and were used as a
positive control.
Immunocytochemical staining of CAFs
Immunocytochemical staining of CAFs was conducted
using a streptavidin-biotin-peroxidase complex method
(Histofine; Nichirei, Tokyo, Japan), with primary anti-
bodies against PDPN (413541; mouse monoclonal, D2-
40, Nichirei Bioscience). Cultured cells were fixed on
culture slides for 20 min in methanol/acetone at 4°C.
Endogenous peroxidase activity was blocked by treat-
ment with methanol containing 0.3% hydrogen peroxid-
ase for 20 min. Antigen retrieval was conducted by
microwave heating for 20 min with sodium citrate buffer
(pH 6.0). After exposure to 10% non-immunized goat
serum in PBS for 20 min, sections were incubated with
primary antibody at room temperature for 90 min. Sub-
sequent reactions were performed according to the
peroxidase-labeled streptavidin-biotin technique using a
histofine SAB-PO kit (Nichirei). The reaction products
were visualized using diaminobenzidine tetrahydrochlo-
ride as a chromogen. Finally, the sections were counter-
stained with hematoxylin. Harvested CAFs were treated
with trypsin/EDTA for 5 min, then centrifuged at
1,600 × g. for 5 min and fixed for 3 h by mixing with
5 mL 10% formalin. Cells were centrifuged for 5 min
and the supernatant was removed, followed by the
addition of 0.5 ml 1% sodium alginate. After centrifuga-
tion for a further 5 min, 2 drops of 1 M calcium chloride
solution were added. The concretions were embedded in
paraffin. Sections were cut at 4 μm and stained with
PDPN.
Real-time qRT-PCR
One-step real-time qRT-PCR with gene-specific priming
was performed as described previously [13]. The total RNA
was extracted from cultured cells using a High Pure RNA
Isolation Kit (Roche Diagnostics, Mannheim, Germany)
and DNase I (Roche Diagnostics) treatment according to
the manufacturer’s instructions. One-step real-time qRT-
PCR was performed using a QuantiTect SYBR Green
Reverse Transcription-PCR Kit (Qiagen, Tokyo, Japan)
and a CFX96 Touch Real-Time PCR Detection System
(Bio-Rad Laboratories, Hercules, CA). Primers for PDPN,
CD10, MMP2, MMP3, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), and 18S ribosomal RNA
(18SrRNA) were purchased from Takara Bio Inc. (Tokyo,
Japan). The primer sequences are listed in Additional file 5:
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for 30 minutes to allow reverse transcription in which first-
strand complementary DNA was synthesized by priming
total RNA with a gene-specific primer. PCR was initiated
by incubation at 95°C for 15 minutes to activate the
polymerase, followed by 40 cycles of 95°C for 5 seconds,
60°C for 20 seconds, and 72°C for 30 seconds. The gene
expression levels were calculated using a standard curve
constructed with total RNA from H157 (a lung squamous
cell line), SUIT-2 (a pancreatic cancer cell line), or specific
CAFs. The levels of gene expression were normalized to
those of GAPDH or 18SrRNA as an internal control and
calculated as the ratio of target gene expression to GAPDH
or 18SrRNA expression. The quantitative ranges of thresh-
old cycles observed were 15–35 cycles for each of the tar-
get genes and 5–25 cycles for GAPDH and 18SrRNA. All
samples were run in triplicate, and each sample was ana-
lyzed three times. No detectable PCR products were ampli-
fied without prior reverse transcription. The accuracy and
integrity of the PCR products were confirmed using an
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo
Alto, CA).
Immunofluorescence staining
CAFs were plated on glass-bottom dishes (Matsunami,
Osaka, Japan) and incubated for 24 hours in DMEM sup-
plemented with 10% FBS. The cells were then fixed with
methanol, blocked with 3% bovine serum albumin in PBS,
and incubated with mouse monoclonal anti-α-SMA
(N1584; 1:50; Dako) or rabbit polyclonal anti-PDPN
(sc-134482; 1:50; Santa Cruz Biotechnology, Santa Cruz,
CA) antibodies overnight at 4°C. The cells were then incu-
bated with Alexa Fluor 546-conjugated anti-mouse IgG
and Alexa Fluor 488-conjugated anti-rabbit IgG (Molecular
Probes, Eugene, OR) for 1 hour. Nuclei were counter-
stained with 4′,6-diamidino-2-phenylindole (0.05 mg/ml).
Labeled cells were observed under a fluorescence micro-
scope (BZ-9000E; Keyence, Osaka, Japan), and images were
obtained using a BZ-II analyzer (Keyence, Osaka, Japan).
Flow cytometric analysis
Subconfluent cells were harvested by exposure to tryp-
sin/EDTA for 5 minutes at 37°C, and then washed in
DMEM/10% FBS. The cells were resuspended in 1%
FBS/PBS at 1 × 106 cells/95 μl and incubated with 5 μl
phycoerythrin (PE)-conjugated anti-PDPN antibody (12–
9381; eBioscience Inc., San Diego, CA) on ice for 30 mi-
nutes. We also stained cells with nonspecific rat IgG2
Control PE (12–4321; eBioscience Inc.) for the negative
control. To detect FAP positive cells, the cells were re-
suspended in 1% FBS/PBS at 1 × 106 cells/95 μl and in-
cubated with 5 μl (2.5 μg) anti-human FAP mouse
monoclonal antibody (MAB3715; R&D) on ice for 30 mi-
nutes. After washing twice, the cells in 99 μl of 1% FBS/PBS were incubated with 1 μl of allophycocyanin (APC)
anti-mouse IgG antibodies (Sony Corporation, Tokyo,
Japan) on ice for 30 minutes. Labeled cells were analyzed
using a flow cytometer (EC800; Sony) equipped with a
laser that provided an excitation wavelength of 488 nm
for PE and 642 nm for APC. Data were analyzed using
Eclipse Analysis software (Sony).
Isolation of CAFs by immunoreactivity for PDPN
After labeling the cells with PE-conjugated anti-PDPN
antibody, we added magnetic microbeads conjugated
with an anti-PE reagent, followed by incubation for
15 minutes at 4°C. PDPN+ cells were isolated by passing
the suspension through an AutoMACS PRO separator
(Miltenyi Biotechnology). The purity of isolated popula-
tions was about 95%. Unlabeled cells were negatively se-
lected and collected by the depletion method through
the AutoMACS PRO separator. Unlabeled cells were al-
most 0% PDPN+.
Indirect co-culture system
Indirect co-culture was performed using a 6-well trans-
well culture system with 3-μm cell culture inserts
(Becton Dickinson Labware, Franklin Lakes, NJ) as de-
scribed previously [38]. CAFs were co-cultured with
pancreatic cancer cells. Two types of CAFs (5 × 104 cells)
were seeded in the lower chambers. After 24 hours of
culture, 5 × 104 cells from cancer cell lines were seeded
in the upper chambers with DMEM supplemented with
2% FBS. After incubation for 72 and 120 hours, we ex-
amined the percentage of PDPN+ CAFs by flow cytome-
try. For the control, the percentage of PDPN+ CAFs in
monoculture was examined.
Migration and matrigel invasion assays
Migration and invasion of cultured cancer cells were
assessed by counting the number of cells migrating or
invading through uncoated or Matrigel-coated transwell
chambers (BD Biosciences, Franklin Lakes, NJ) as de-
scribed previously [49,50]. We used transwell inserts
with 8-μm pores. Uncoated transwell chambers were
used for the migration assay, and chambers coated with
20 μg/well Matrigel (BD Biosciences, Bedford, MA) were
used for the invasion assay. Cancer cells (5 × 104 cells/
ml, 0.25 ml medium) were seeded in the upper cham-
bers. For co-cultures, 5 × 104 CAFs/0.75 ml medium
were seeded in the lower chambers at 24 hours before
cancer cell seeding. The cells were then incubated for
18 hours (PANC-1) and 24 hours (SUIT-2) for the mi-
gration assay, and 24 hours (PANC-1) and 48 hours
(SUIT-2) for the invasion assay. Cancer cells at the lower
surface of the membrane were fixed with 70% ethanol,
stained with hematoxylin and eosin, and counted in five
random fields at × 200 magnification under a microscope.
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independent experiments were repeated at least three
times.
Silencing of PDPN by siRNA
We performed knockdown of PDPN by siRNA according
to the manufacturer’s instructions. CAFs (1 × 105 cells)
were transfected with PDPN-1 siRNA (si1) and T1A-2
siRNA (si2) siRNA (Qiagen)/Lipofectamine RNAiMax
transfection reagent (Invitrogen)/Opti-MEM (Invitrogen)
complexes for the indicated time. After transfection, the
cells were cultured in fresh DMEM containing 10% FBS at
37°C. The effect of siRNA was confirmed by qRT-PCR and
western blotting. To verify the specificity of knockdown,
we used negative control siRNA (Qiagen). CAFs were used
in subsequent experiments at 72 hours after transfection.
Western blotting analysis
Protein was extracted from CAFs using PRO-PREP
(iNtRON biotechnology, Seongnam, Korea) according to
the manufacturer’s instructions. From each sample, 20 μg
of protein was run on a 4% to 12% gradient Bis-Tris–HCl
buffered (pH 6.4) polyacrylamide gel (NuPAGE Novex 4–
12% Bis-Tris Gel, Invitrogen, Life Technologies, Carlsbad,
CA) and transferred to a polyvinylidene difluoride mem-
brane (Millipore, Billerica, MA). The membrane was incu-
bated overnight at 4°C with anti-PDPN (11–003; 1:200;
AngioBio Co., Del Mar, CA), anti-CD10 (NCL-CD10-270;
1:100; Novocastra, Newcastle Upon Tyne, UK), or anti-α-
tubulin (05–829; 1:1000; Millipore, Billerica, MA) antibodies
and then probed with secondary antibodies conjugated to
horseradish peroxidase (Santa Cruz Biotechnology). Immu-
noblots were detected by enhanced chemiluminescence with
ChemiDoc XRS (Bio-Rad Laboratories).
Statistical analysis
Values were expressed as the mean ± standard deviation.
Comparisons between two groups were made using the
Student’s t-test. All experiments were repeated three times.
Statistical significance was defined as P < 0.05. The χ2 test
was used to analyze correlations between immunohisto-
chemical staining of PDPN and clinicopathologic charac-
teristics. Survival curves were constructed using the
Kaplan-Meier method and compared using the log-rank
test. To evaluate independent prognostic factors associated
with survival, a multivariate Cox proportional-hazards re-
gression analysis was used. All statistical analyses were per-
formed using JMP 8.0 software (SAS Institute, Cary, NC).
Additional files
Additional file 1: Figure S1. Flow cytometric analysis and
immunocytochemical staining of CAFs to characterize. (A) The rate of
PDPN expression in CAFs did not differ according to the length oftrypsin/EDTA treatment after 2, 5, and 10 minutes. (B)
Immunocytochemical staining of PDPN for cultured CAFs (upper) and
harvested CAFs after trypsin/EDTA treatment for 5 min (lower). Original
magnification ×400. (C) All the primary cultured CAFs (CAF1, CAF2, CAF3, and
CAF4) were positive for FAP in most cells.
Additional file 2: Figure S2. CAFs (CAF3 and CAF4) were sorted into
two populations based on their expression of PDPN to investigate the
biological functions of PDPN+ CAFs. (A) Analysis of the PDPN+
population among parental CAF4 cells (left) and reanalysis of the sorted
PDPN+ cells (right upper, 90.8% PDPN+ cells) and PDPN– cells (right
lower, 0.44% PDPN+ cells). (B) qRT-PCR was performed to measure the
PDPN mRNA expression in CAF1 cells, CAF2 cells, and sorted PDPN+ and
PDPN– CAFs.
Additional file 3: Figure S3. PDPN knockdown in CAF1 cells by siRNA.
Transfection of PDPN-1 siRNA (si1) and T1A-2 siRNA (si2) decreased PDPN
mRNA expression (A) resulting in decreased levels of PDPN protein in
cells as shown by western blotting at the indicated times (B). Knockdown
of PDPN in CAF1 cells by siRNA showed no differences in the migration
(C) or invasion (D) of PANC-1 and SUIT-2 cells compared with the control
cells (n.s.: not significant).
Additional file 4: Table S1. Clinicopathological characteristics of the
105 patients with pancreatic IDC.
Additional file 5: Table S2. Primers used for qRT-PCR.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YO formulated the study design. KS and SA designed the experiments,
carried out the study, and prepared the manuscript. KO supervised the
statistical analysis and revised the manuscript. KF provided clinical data
including prognostic markers and survival. MF, YM, and MH performed the
histopathological assessments of the patients. KM and MT supervised the
interpretations of results, and revised the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
We thank N. Tateishi (Department of Anatomic Pathology, Kyushu University
Hospital) and E. Manabe (Department of Surgery and Oncology, Kyushu
University Hospital) for their expert technical assistance. We also thank Edanz
Group Japan for English language editing.
Financial support
This work was supported in part by a Grant-in-Aid for Japan Society for the
Promotion of Science (JSPS) fellows.
Author details
1Department of Anatomic Pathology, Graduate School of Medical Sciences,
Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan. 2Department of
Surgery and Oncology, Graduate School of Medical Sciences, Kyushu
University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan. 3Advanced Medical
Initiatives, Graduate School of Medical Sciences, Kyushu University, 3-1-1
Maidashi, Fukuoka 812-8582, Japan. 4Kyushu University Hospital Cancer
Center, Fukuoka 812-8582, Japan. 5Research Fellow of Japan Society for the
Promotion of Science, Tokyo, Japan.
Received: 16 July 2013 Accepted: 16 December 2013
Published: 20 December 2013
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63:11–30.
2. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S,
Hanna S, Taylor B, Langer B, Gallinger S: Prognostic factors in resected
pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll
Surg 2004, 198:722–731.
3. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji
B, Evans DB, Logsdon CD: Cancer-associated stromal fibroblasts promote
pancreatic tumor progression. Cancer Res 2008, 68:918–926.
Shindo et al. Molecular Cancer 2013, 12:168 Page 15 of 16
http://www.molecular-cancer.com/content/12/1/1684. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Canc 2006, 6:392–401.
5. Couvelard A, O’Toole D, Leek R, Turley H, Sauvanet A, Degott C, Ruszniewski
P, Belghiti J, Harris AL, Gatter K, Pezzella F: Expression of hypoxia-inducible
factors is correlated with the presence of a fibrotic focus and
angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005,
46:668–676.
6. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP,
Buchholz M, Olive KP, Gress TM, Tuveson DA: Stromal biology and therapy
in pancreatic cancer. Gut 2011, 60:861–868.
7. Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA,
Pirola RC, Wilson JS: Periacinar stellate shaped cells in rat pancreas:
identification, isolation, and culture. Gut 1998, 43:128–133.
8. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A,
Siech M, Beger H, Grunert A, Adler G: Identification, culture, and
characterization of pancreatic stellate cells in rats and humans.
Gastroenterology 1998, 115:421–432.
9. Erkan M, Adler G, Apte MV, Bachem MG, Buchholz M, Detlefsen S, Esposito I,
Friess H, Gress TM, Habisch HJ, Hwang RF, Jaster R, Kleeff J, Kloppel G,
Kordes C, Logsdon CD, Masamune A, Michalski CW, Oh J, Phillips PA, Pinzani
M, Reiser-Erkan C, Tsukamoto H, Wilson J: StellaTUM: current consensus
and discussion on pancreatic stellate cell research. Gut 2012, 61:172–178.
10. Masamune A, Watanabe T, Kikuta K, Shimosegawa T: Roles of pancreatic
stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol
Hepatol 2009, 7:S48–54.
11. Habisch H, Zhou S, Siech M, Bachem MG: Interaction of stellate cells with
pancreatic carcinoma cells. Cancers 2010, 2:1661–1682.
12. Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H,
Hart IR, Kocher HM: Retinoic acid-induced pancreatic stellate cell
quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor
progression. Gastroenterology 2011, 141:1486–1497. 1497 e1481-1414.
13. Ikenaga N, Ohuchida K, Mizumoto K, Cui L, Kayashima T, Morimatsu K,
Moriyama T, Nakata K, Fujita H, Tanaka M: CD10+ pancreatic stellate cells
enhance the progression of pancreatic cancer. Gastroenterology 2010,
139:1041–1051. 1051 e1041-1048.
14. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber
E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D: Angiosarcomas
express mixed endothelial phenotypes of blood and lymphatic
capillaries: podoplanin as a specific marker for lymphatic endothelium.
Am J Pathol 1999, 154:385–394.
15. Matsui K, Breitender-Geleff S, Soleiman A, Kowalski H, Kerjaschki D:
Podoplanin, a novel 43-kDa membrane protein, controls the shape of
podocytes. Nephrol Dial Transplant 1999, 14(Suppl 1):9–11.
16. Rishi AK, Joyce-Brady M, Fisher J, Dobbs LG, Floros J, VanderSpek J, Brody JS,
Williams MC: Cloning, characterization, and development expression of a
rat lung alveolar type I cell gene in embryonic endodermal and neural
derivatives. Dev Biol 1995, 167:294–306.
17. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M:
Up-regulation of the lymphatic marker podoplanin, a mucin-type
transmembrane glycoprotein, in human squamous cell carcinomas and
germ cell tumors. Am J Pathol 2005, 166:913–921.
18. Ordonez NG: The diagnostic utility of immunohistochemistry and
electron microscopy in distinguishing between peritoneal
mesotheliomas and serous carcinomas: a comparative study. Mod Pathol
2006, 19:34–48.
19. Wicki A, Christofori G: The potential role of podoplanin in tumour
invasion. Br J Cancer 2007, 96:1–5.
20. Suzuki H, Onimaru M, Yonemitsu Y, Maehara Y, Nakamura S, Sueishi K:
Podoplanin in cancer cells is experimentally able to attenuate
prolymphangiogenic and lymphogenous metastatic potentials of lung
squamoid cancer cells. Mol Cancer 2010, 9:287.
21. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L:
Overexpression of podoplanin in oral cancer and its association with
poor clinical outcome. Cancer 2006, 107:563–569.
22. Xu Y, Ogose A, Kawashima H, Hotta T, Ariizumi T, Li G, Umezu H, Endo N:
High-level expression of podoplanin in benign and malignant soft tissue
tumors: immunohistochemical and quantitative real-time RT-PCR
analysis. Oncol Rep 2011, 25:599–607.
23. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan
CT, Pastan IH, Bigner DD: Recombinant anti-podoplanin (NZ-1)
immunotoxin for the treatment of malignant brain tumors. Int J Canc
Suppl J Int Canc Suppl 2013, 132:2339–2348.24. Kaneko MK, Kato Y, Kitano T, Osawa M: Conservation of a platelet
activating domain of Aggrus/podoplanin as a platelet aggregation-
inducing factor. Gene 2006, 378:52–57.
25. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, Fukayama M: Podoplanin
is regulated by AP-1 and promotes platelet aggregation and cell
migration in osteosarcoma. Am J Pathol 2011, 179:1041–1049.
26. Scholl FG, Gamallo C, Vilaro S, Quintanilla M: Identification of PA2.26
antigen as a novel cell-surface mucin-type glycoprotein that induces
plasma membrane extensions and increased motility in keratinocytes.
J Cell Sci 1999, 112(Pt 24):4601–4613.
27. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G: Tumor
invasion in the absence of epithelial-mesenchymal transition:
podoplanin-mediated remodeling of the actin cytoskeleton. Cancer cell
2006, 9:261–272.
28. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M:
Podoplanin binds ERM proteins to activate RhoA and promote
epithelial-mesenchymal transition. J Cell Sci 2006, 119:4541–4553.
29. Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y,
Tsuneyoshi M: Lymphatic spread is related to VEGF-C expression and D2-
40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod
Pathol 2008, 21:256–264.
30. Carvalho FM, Zaganelli FL, Almeida BGL, Goes JCS, Baracat EC, Carvalho JP:
Prognostic value of podoplanin expression in intratumoral stroma and
neoplastic cells of uterine cervical carcinomas. Clinics 2010,
65:1279–1283.
31. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, Sasaki H, Ochiai A:
Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor
formation: podoplanin in fibroblast functions for tumor progression.
Cancer Res 2011, 71:4769–4779.
32. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura
M, Yoshida J, Suzuki K, Ochiai A: Podoplanin expression by cancer
associated fibroblasts predicts poor prognosis of lung adenocarcinoma.
Int J Cancer 2008, 123:1053–1059.
33. Kitano H, Kageyama S, Hewitt SM, Hayashi R, Doki Y, Ozaki Y, Fujino S,
Takikita M, Kubo H, Fukuoka J: Podoplanin expression in cancerous stroma
induces lymphangiogenesis and predicts lymphatic spread and patient
survival. Arch Pathol Lab Med 2010, 134:1520–1527.
34. Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, Calik J, Wojnar
A, Witkiewicz W, Rys J, Ugorski M, Dziegiel P, Podhorska-Okolow M:
Podoplanin expression by cancer-associated fibroblasts predicts poor
outcome in invasive ductal breast carcinoma. Histopathology 2011,
59:1249–1260.
35. Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y,
Watanabe M, Hirohashi S: Podoplanin expression identified in stromal
fibroblasts as a favorable prognostic marker in patients with colorectal
carcinoma. Oncology 2009, 77:53–62.
36. Zhang Y, Tang H, Cai J, Zhang T, Guo J, Feng D, Wang Z: Ovarian
cancer-associated fibroblasts contribute to epithelial ovarian carcinoma
metastasis by promoting angiogenesis, lymphangiogenesis and tumor
cell invasion. Cancer Lett 2011, 303:47–55.
37. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds): Exocrine
and Endocrine Pancreas, AJCC cancer staging manual. 7th edition. New York:
Springer; 2010:241–248.
38. Fujita H, Ohuchida K, Mizumoto K, Egami T, Miyoshi K, Moriyama T, Cui L, Yu
J, Zhao M, Manabe T, Tanaka M: Tumor-stromal interactions with direct
cell contacts enhance proliferation of human pancreatic carcinoma cells.
Cancer Sci 2009, 100:2309–2317.
39. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in
cancer progression. Nat Rev Canc 2002, 2:161–174.
40. Seiki M: The cell surface: the stage for matrix metalloproteinase
regulation of migration. Curr Opin Cell Biol 2002, 14:624–632.
41. Cirri P, Chiarugi P: Cancer associated fibroblasts: the dark side of the coin.
American journal of cancer research 2011, 1:482–497.
42. Madar S, Goldstein I, Rotter V: ‘Cancer associated fibroblasts’–more than
meets the eye. Trends Mol Med 2013, 19:447–453.
43. Erez N, Truitt M, Olson P, Arron ST, Hanahan D: Cancer-associated
fibroblasts are activated in incipient neoplasia to orchestrate
tumor-promoting inflammation in an NF-kappaB-dependent manner.
Cancer Cell 2010, 17:135–147.
44. Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD:
FAP-overexpressing fibroblasts produce an extracellular matrix that
Shindo et al. Molecular Cancer 2013, 12:168 Page 16 of 16
http://www.molecular-cancer.com/content/12/1/168enhances invasive velocity and directionality of pancreatic cancer cells.
BMC Cancer 2011, 11:245.
45. Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M,
Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP,
O’Rahilly S, Brindle KM, Teichmann SA, Tuveson DA, Fearon DT: Depletion
of stromal cells expressing fibroblast activation protein-alpha from
skeletal muscle and bone marrow results in cachexia and anemia.
J Exp Med 2013, 210:1137–1151.
46. Fujita H, Ohuchida K, Mizumoto K, Nakata K, Yu J, Kayashima T, Cui L,
Manabe T, Ohtsuka T, Tanaka M: Alpha-smooth muscle actin expressing
stroma promotes an aggressive tumor biology in pancreatic ductal
adenocarcinoma. Pancreas 2010, 39:1254–1262.
47. Hruban RH, Klöppel G, Boffetta P, Maitra A, Hiraoka N, Offerhaus GJA,
Lacobuzio-Donahue C, Pitman MB, Kato Y, Kern SE, Klimstra DS: Ductal
adenocarcinoma of the pancreas. In WHO classification of tumours of the
digestive system. World Health Organization; 2010:281–291.
48. Eguchi D, Ikenaga N, Ohuchida K, Kozono S, Cui L, Fujiwara K, Fujino M,
Ohtsuka T, Mizumoto K, Tanaka M: Hypoxia enhances the interaction
between pancreatic stellate cells and cancer cells via increased secretion
of connective tissue growth factor. J Surg Res 2013, 181:225–233.
49. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E,
Matsumoto K, Nakamura T, Tanaka M: Radiation to stromal fibroblasts
increases invasiveness of pancreatic cancer cells through tumor-stromal
interactions. Cancer Res 2004, 64:3215–3222.
50. Iwamoto Y, Tanaka K, Okuyama K, Sugioka Y, Taniguchi S: In vitro assay of
the invasive potential of malignant bone and soft tissue tumours
through basement membranes. Int Orthop 1994, 18:240–247.
doi:10.1186/1476-4598-12-168
Cite this article as: Shindo et al.: Podoplanin expression in cancer-
associated fibroblasts enhances tumor progression of invasive ductal
carcinoma of the pancreas. Molecular Cancer 2013 12:168.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
